医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Otsuka Pharmaceutical’s POCARI SWEAT to Be Official Drink for Two Consecutive Asian Games

2014年01月20日 PM01:25
このエントリーをはてなブックマークに追加

Smart Multimedia Gallery

 

Signing Ceremony at the Olympic Council of Asia in Manila, the Philippines (Photo: Business Wire)Signing Ceremony at the Olympic Council of Asia in Manila, the Philippines (Photo: Business Wire)

View and Share Photo

Close Window


TOKYO

Otsuka Pharmaceutical Co., Ltd. (Head office: Chiyoda-ku, Tokyo; President, Representative Director: Taro Iwamoto) signed a partnership agreement with the Olympic Council of Asia (OCA) for the 2014 Incheon Asian Games (Korea) and the 2019 Hanoi Asian Games (Vietnam) during the General Assembly held in Manila, the Philippines, on January 18. The Asian Games are organized by OCA and are the largest comprehensive sports event in the region of Asia.

Signing Ceremony at the Olympic Council of Asia in Manila, the Philippines (Photo: Business Wire)

Signing Ceremony at the Olympic Council of Asia in Manila, the Philippines (Photo: Business Wire)

  • A partnership agreement has been signed for the Incheon Asian Games (Korea) in September 2014 and the 2019 Hanoi Asian Games (Vietnam). The Asian Games are the largest sports event in Asia.
  • The population of Asian Games member countries totals approximately 3.8 billion*1, which accounts for about half of the world population. Otsuka Pharmaceutical believes that sports are an important element of health for people in Asian countries, which are growing and changing dynamically, and will supply POCARI SWEAT as the official drink. This ion beverage is sold in 17 countries and regions, mainly in Asia. POCARI SWEAT quickly replenishes fluids and electrolytes lost through perspiration to support athlete conditioning and aid maximum performance. Otsuka Pharmaceutical is currently the sole Japanese partner of the Games. *2
  • Otsuka Pharmaceutical first expanded overseas 40 years ago, starting with Asia (Thailand in 1973, Taiwan and Indonesia in 1974). The OIAA*3 Division is currently expanding both pharmaceuticals and nutraceuticals*4 businesses in Asian and Arab countries and business scale has grown tenfold in the last decade.

*1 Total population of the 45 OCA-member countries/regions (source: Ministry of Foreign Affairs of Japan website)
*2 As of January 20, 2014
*3 Otsuka International Asia Arab
*4 Nutraceuticals: nutrition + pharmaceuticals. Products developed with scientific basis to help maintain and promote everyday well-being.

News Release Distribution System
We offer a system to deliver Otsuka Pharmaceutical’s latest news releases directly to you.
Go to our website (URL) and register by clicking the RSS button at the top right on our page of news releases.
http://www.otsuka.co.jp/company/release/release.xml

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20140119005033/en/

CONTACT

Please contact the below for any inquiries regarding this matter.
Otsuka
Pharmaceutical Co., Ltd.
+81-3-6361-7379 (direct line)
Public
Relations Department
FAX: +81-3-6717-1479
URL: http://www.otsuka.co.jp/en/

同じカテゴリーの記事 

  • 基于LC-Plasma的疫苗研究入选SCARDA项目
  • LC-Plasma-based Vaccine Research Selected for SCARDA Project
  • 一份具有里程碑意义的报告证明,大量使用尼古丁不会导致健康问题高发
  • Modalis Therapeutics Reports Data Supporting Development of a Transformative Epigenome Editing Therapeutic, MDL-101: a First-in-Class Epigenome Editing approach for the Treatment of LAMA2-deficient congenital muscular dystrophy (LAMA2-CMD)
  • Galderma Receives Filing Acceptances for Nemolizumab in Prurigo Nodularis and Atopic Dermatitis in Four Additional Countries